Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

An Open Label Study of Electroencephalographic Responses Pre, During and Post, a Low Dose, Weekly Intravenous Ketamine Infusion for 4 Weeks, in a Study Population With Major Depression Disorder

To see complete record on, please visit this link

Id: NCT05506462

Organisation Name: Ehave Inc.

Overal Status: Not yet recruiting

Start Date: January 2023

Last Update: August 22, 2022

Lead Sponsor: Ehave Inc.

Brief Summary: There are many common pharmacological treatments for major depression disorder (MDD), however the efficacy of these drugs often fails in severe cases. Intravenous (IV) administered ketamine may offer the potential for remission of the symptoms in patients with MDD; however it has not yet been approved by FDA for this purpose. This study will make use of an electroencephalography (EEG) machine to measure the brain's activity and response while the IV ketamine is being delivered. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions.

  • Major Depressive Disorder

Total execution time in seconds: 0.19567394256592